Articles From: Amgen Announces Positive Top-Line Results From Phase 3 LAPLACE-2 Trial Of Evolocumab (AMG 145) In Combination With Statins In Patients With High Cholesterol to Amgen To Present At The Morgan Stanley Global Healthcare Conference


2014/1/28
Study Meets Co-Primary Endpoints of LDL Cholesterol Reduction THOUSAND OAKS, Calif.
Sign-up for Amgen Announces Positive Top-Line Results From Phase 3 LAPLACE-2 Trial Of Evolocumab (AMG 145) In Combination With Statins In Patients With High Cholesterol investment picks
2013/12/17
Study Meets Co-Primary Endpoints of LDL Cholesterol Reduction THOUSAND OAKS, Calif.
Sign-up for Amgen Announces Positive Top-Line Results From Phase 3 MENDEL-2 Trial Of Evolocumab (AMG 145) In Patients With High Cholesterol investment picks
2014/1/30
RUTHERFORD-2 Study Meets Co-Primary Endpoints of LDL Cholesterol Reduction Amgen Also Announces Results From Phase 3 Study With Automated Mini-Doser Completion of Fifth Phase 3 Study Forms Basis For Global Filing Plan THOUSAND OAKS, Calif.
Sign-up for Amgen Announces Positive Top-Line Results From Phase 3 RUTHERFORD-2 Trial Of Evolocumab (AMG 145) In Patients With Heterozygous Familial Hypercholesterolemia investment picks
2014/3/17
Study Meets Primary Endpoint of LDL Cholesterol Reduction First Phase 3 Data of a PCSK9 Inhibitor in Patients With Homozygous Familial Hypercholesterolemia - A Rare and Serious Disease THOUSAND OAKS, Calif.
Sign-up for Amgen Announces Positive Top-Line Results From Phase 3 TESLA Trial Of Evolocumab (AMG 145) In Patients With Homozygous Familial Hypercholesterolemia investment picks
2014/1/23
THOUSAND OAKS, Calif.
Sign-up for Amgen Announces Webcast of 2013 Fourth Quarter and Full Year Financial Results investment picks
2013/10/17
THOUSAND OAKS, Calif.
Sign-up for Amgen Announces Webcast of 2013 Third Quarter Financial Results investment picks
Innovative Program - Amgen Biotech Experience - Brings Real-World Biotechnology Lab Experience to Students THOUSAND OAKS, Calif.
Sign-up for Amgen Foundation Commits $2.5 Million In New Grants To Engage 50,000 Students Each Year In The Thrill Of Scientific Inquiry investment picks
THOUSAND OAKS, Calif.
Sign-up for Amgen Highlights Data To Be Presented At 2013 European Cancer Congress investment picks
2013/10/4
Prolia Open-Label Extension Trial Showed Continued Increases in Bone Mineral Density and Low Fracture Incidence for Up to Eight Years THOUSAND OAKS, Calif.
Sign-up for Amgen Presents Nearly Two Dozen Abstracts From Romosozumab And Prolia® (Denosumab) At ASBMR investment picks
2013/9/30
THOUSAND OAKS, Calif.
Sign-up for Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma investment picks
2013/9/1
Pooled Data from Four Phase 2 Studies Demonstrated Consistent Reductions in LDL Cholesterol of Up to 59 Percent Results of Analyses Presented at ESC Congress 2013 THOUSAND OAKS, Calif.
Sign-up for Amgen Presents Pooled Analysis Showing AMG 145 Significantly Reduced LDL Cholesterol In Over 1,200 Patients investment picks
Amgen Inc. said its fourth-quarter earnings rose 30% as the biopharmaceutical company reported sales growth for most of its products.
Sign-up for Amgen Profit Rises 30% on Broad Sales Growth investment picks
Amgen Inc.'s (AMGN) third-quarter earnings rose 24% amid broad revenue growth across the biopharmaceutical company's portfolio.
Sign-up for Amgen Profit Up 24% Amid Broad Sales Growth investment picks
2014/4/4
THOUSAND OAKS, Calif.
Sign-up for Amgen Provides Update On Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma investment picks
2014/3/17
By Nicholas Hatcher Amgen Inc. (AMGN) said its Phase 3 trial studying its Evolocumab cholesterol drug met its primary endpoint of the reduction in LDL-C, or "bad" cholesterol.
Sign-up for Amgen Says Cholesterol Drug Study Meets Primary Endpoint investment picks
By Dana Cimilluca and Jonathan D.
Sign-up for Amgen strikes $10.4 billion deal for Onyx investment picks
Acquisition Expected to Close Today Deal Valued at $9.7 Billion THOUSAND OAKS, Calif.
Sign-up for Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer investment picks
2013/8/25
Attractive Addition to Amgen's Leading Oncology Portfolio and Pipeline Kyprolis® (carfilzomib) for Injection is at Early Stages of Launch in Multiple Myeloma; Showing Strong Physician Support Acquisition Expected to Contribute to Growth and Value for Amgen Shareholders Amgen to Host Analyst/Investor Call Monday at 8:30 a.m. EDT (5:30 a.m. PDT) THOUSAND OAKS, Calif.
Sign-up for Amgen To Acquire Onyx Pharmaceuticals For $125 Per Share In Cash investment picks
THOUSAND OAKS, Calif.
Sign-up for Amgen to Highlight New Data at Upcoming ESC Congress 2013 investment picks
First Long-Term Data of a PCSK9 Inhibitor to be Featured in Clinical Science: Special Reports Session THOUSAND OAKS, Calif.
Sign-up for Amgen to Highlight New Evolocumab (AMG 145) Data at Upcoming American Heart Association Scientific Sessions 2013 investment picks
THOUSAND OAKS, Calif.
Sign-up for Amgen To Host Post American Society of Hematology (ASH) Summary Webcast investment picks
2013/8/30
THOUSAND OAKS, Calif.
Sign-up for Amgen To Participate At Citi's 8th Annual Biotech Conference investment picks
THOUSAND OAKS, Calif.
Sign-up for Amgen To Present At The 32nd Annual J.P. Morgan Healthcare Conference investment picks
THOUSAND OAKS, Calif.
Sign-up for Amgen To Present At The Bank Of America Merrill Lynch Global Healthcare Conference investment picks
2014/3/1
THOUSAND OAKS, Calif.
Sign-up for Amgen To Present At The Cowen And Company 34th Annual Healthcare Conference investment picks
2013/11/8
THOUSAND OAKS, Calif.
Sign-up for Amgen To Present At The Credit Suisse Annual Healthcare Conference investment picks
THOUSAND OAKS, Calif.
Sign-up for Amgen To Present At The Morgan Stanley Global Healthcare Conference investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Amgen Announces Positive Top-Line Results From Phase 3 LAPLACE-2 Trial Of Evolocumab (AMG 145) In Combination With Statins In Patients With High Cholesterol to Amgen To Present At The Morgan Stanley Global Healthcare Conference
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity